Nabet, Behnam http://orcid.org/0000-0002-6738-4200
Ferguson, Fleur M. http://orcid.org/0000-0003-4091-7617
Seong, Bo Kyung A.
Kuljanin, Miljan
Leggett, Alan L.
Mohardt, Mikaela L.
Robichaud, Amanda
Conway, Amy S.
Buckley, Dennis L.
Mancias, Joseph D.
Bradner, James E. http://orcid.org/0000-0002-2718-4415
Stegmaier, Kimberly http://orcid.org/0000-0003-0218-7895
Gray, Nathanael S. http://orcid.org/0000-0001-5354-7403
Funding for this research was provided by:
American Cancer Society (PF-17-010-01-CDD)
Claudia Adams Barr Program in Innovative Basic Cancer Research Award Katherine L. and Steven C. Pinard Research Fund
U.S. Department of Defense (CA181249)
Damon Runyon Cancer Research Foundation (DRG-2196-14)
Burroughs Wellcome Fund Career Award in Medical Sciences Award Hale Center for Pancreatic Cancer Research
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA231637, CA204915)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 5 February 2020
Accepted: 6 August 2020
First Online: 18 September 2020
Competing interests
: The authors claim the following competing interests: B.N., D.L.B., and J.E.B. are inventors on patent applications related to the dTAG system (WO/2017/024318, WO/2017/024319, WO/2018/148440 and WO/2018/148443). The molecules disclosed in this manuscript are the subject of a patent application filed by Dana-Farber Cancer Institute. D.L.B. is now an employee of Novartis. J.E.B. is a Scientific Founder of Syros Pharmaceuticals, SHAPE Pharmaceuticals, Acetylon Pharmaceuticals, Tensha Therapeutics (now Roche), and C4 Therapeutics and is the inventor on IP licensed to these entities. J.E.B. is now an executive and shareholder in Novartis AG. K.S. has previously consulted for Novartis and Rigel Pharmaceuticals and has received research funding from Novartis. N.S.G. is a Scientific Founder, member of the Scientific Advisory Board (SAB) and equity holder in C4 Therapeutics, Syros, Soltego (board member), B2S, Allorion, Gatekeeper, and Petra Pharmaceuticals. The Gray lab receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Janssen, Kinogen, Voroni, Arbella, Deerfield, and Sanofi. The other authors declare no competing interests.